Enzymatic synthesis of oligonucleotides, an idea ahead of its time in the 1950s, today is ushering in a renaissance in nucleic acids manufacturing by offering a scalable and sustainable solution. In this presentation, Codexis recaps the world’s first enzymatic synthesis of Inclisiran® using its proprietary ECO Synthesis™ technology, showcasing four distinct synthetic routes. The company also highlights the reproducibility when synthesizing siRNA using ECO Synthesis, along with detailed impurity profiling and residual enzyme clearance control strategies.

Speaker:

Derek Gauntlett
Director, Process Chemistry
Nucleic Acid Dev & Manufacturing
Codexis

We'll discuss:

• What new RNA drug delivery technologies are emerging to achieve targeted delivery?
• What considerations need to be made for successful delivery of next generation RNA modalities?
• How can existing methods, such as LNPs, be optimized?

Speakers:

Yacoub Habib
CEO
Ophidion

Bhawanjit Brar
CEO
Jaan Biotherapeutics

Robert Mart
Head of Lead Development
Ochre Bio

Moderator: Sonja Merkas
Founder
Livinovea

The rise of RNA-based therapeutics—including antisense oligonucleotides (ASOs), siRNA, and mRNA—has transformed modern drug discovery. Yet, these modalities come with complex workflows, cross-functional coordination, and high data volumes that challenge many organizations. In this webinar, we’ll walk through a complete end-to-end RNA therapeutic R&D workflow using SignalsOne, Revvity Signals’ integrated scientific platform.

We’ll showcase how the Design-Make-Test-Decide (DMTD) workflow can be streamlined within a single environment, helping research teams go from idea to lead candidate faster, more collaboratively, and with higher confidence.

Starting with ASO design, we’ll demonstrate how ChemDraw-powered HELM notation simplifies oligo construction and design capture, standardizing inputs for downstream workflows. We'll then move into Signals Notebook, where scientists can register and document synthesis, analytical characterization, and assay protocols—all connected within the same system. Finally, we’ll highlight how SignalsOne analytics capabilities—powered by native algorithms and Spotfire visualizations—enable robust multiparameter analysis to identify promising candidates based on biological efficacy, stability, and off-target risk.

By consolidating disparate tools and data silos into a single, connected platform, SignalsOne accelerates decision-making and empowers R&D teams to focus more on innovation and less on wrangling data.

Speakers:

Lindsay Richershauser Ph.D.
Product Manager for ChemDraw
Revvity Signals

Larry Mulcahy Ph.D.
Product Manager for Biologics
Revvity Signals

Zev Wisotsky Ph.D.
Senior Principal Marketing Manager for Biologics Solutions
Revvity Signals

We'll discuss:

• How can we maximize the use of AI in the RNA space?
• How does data quality limit the usefulness of AI, and how must the industry move to overcome this?
• What are the current regulatory considerations must be made when leveraging AI for RNA therapeutics?

Speakers:

Rabia Khan
CEO
Serna Bio

Generoso Ianniciello
CBO
Anima Biotech

Jeff Milton
CTO
La Jolla Labs

Moderator: Tamar Grossman
CEO
La Jolla Labs